International cohort study indicates no association between alpha-1 blockers and susceptibility to COVID-19 in benign prostatic hyperplasia patients

• Main Authors: Akihiko Nishimura (Author), Junqing Xie (Author), Kristin Kostka (Author), Talita Duarte-Salles (Author), Sergio Fernández Bertolín (Author), María Aragón (Author), Clair Blacketer (Author), Azza Shoaibi (Author), Scott L. DuVall (Author), Kristine Lynch (Author), Michael E. Matheny (Author), Thomas Falconer (Author), Daniel R. Morales (Author), Mitchell M. Conover (Author), Seng Chan You (Author), Nicole Pratt (Author), James Weaver (Author), Anthony G. Sena (Author), Martijn J. Schuemie (Author), Jenna Reps (Author), Christian Reich (Author), Peter R. Rijnbeek (Author), Patrick B. Ryan (Author), George Hripcsak (Author), Daniel Prieto-Alhambra (Author), Marc A. Suchard (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Purpose: Alpha-1 blockers, often used to treat benign prostatic hyperplasia (BPH), have been hypothesized to prevent COVID-19 complications by minimising cytokine storm release. The proposed treatment based on this hypothesis currently lacks support from reliable real-world evidence, however. We lev...